Centaurus Financial’s Myriad Genetics MYGN Stock Holding History

Centaurus Financial’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-111	Closed	-$4K	–	1479
2018 Q2	$4K	Buy	+111	New	+$3.75K	﹤0.01%	1868

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Centaurus Financial's MYGN Position: Q3 2018 in Review

Centaurus Financial sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 111 shares — an estimated $4K sold.

Centaurus Financial first reported a position in MYGN in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

Centaurus Financial reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 111 Myriad Genetics shares in Q3 2018, an estimated $4K.
Centaurus Financial first reported a position in Myriad Genetics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Myriad Genetics position peaked at $4K in Q2 2018.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.